Immune-related tumour response assessment criteria: a comprehensive review

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know

(2017) Marta Braschi-Amirfarzan et al.   KOREAN JOURNAL OF RADIOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy

(2016) Stephanie A. Holler Howard et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

(2016) Leila Khoja et al.   BRITISH JOURNAL OF CANCER

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology

(2015) A. Hoos et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy

(2015) Thomas Pyka et al.   Radiation Oncology

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

(2015) Jennifer J. Kwak et al.   RADIOGRAPHICS

Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer

(2015) Chintan Parmar et al.   Scientific Reports

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

(2015) S. H. Tirumani et al.   Cancer Immunology Research

Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care

(2014) Poonamalle Parthasarathy Bapsy et al.   CYTOTHERAPY

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

(2014) Vanna Chiarion Sileni et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

(2014) Stéphane Champiat et al.   Journal of Thoracic Oncology

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

(2014) Mizuki Nishino et al.   Journal for ImmunoTherapy of Cancer

Complications of Targeted Drug Therapies for Solid Malignancies: Manifestations and Mechanisms

(2013) Richard G. Abramson et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria

(2013) Temel Tirkes et al.   RADIOGRAPHICS

Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST

(2012) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies

(2012) Rajul K. Jain et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy

(2011) Kevin N. O'Regan et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy

(2011) Yulia Bronstein et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer

(2009) Binsheng Zhao et al.   RADIOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations

(2008) Chikako Suzuki et al.   RADIOGRAPHICS

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

(2008) F Stephen Hodi et al.   Nature clinical practice. Oncology